Android app on Google Play

Barclays Downgrades Halozyme Therapeutics (HALO) to Equalweight

August 2, 2013 6:58 AM EDT Send to a Friend
Get Alerts HALO Hot Sheet
Price: $9.43 -3.28%

Rating Summary:
    8 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 9 | New: 11
Trade HALO Now!
Join SI Premium – FREE
Barclays downgraded Halozyme Therapeutics (NASDAQ: HALO) from Overweight to Equalweight with a price target of $8.00 (from $9.00).

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $7.32 yesterday.




You May Also Be Interested In


Related Categories

Downgrades

Related Entities

Barclays

Add Your Comment